Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 6/20 | 0.50 |
| ▸ | HRH1 | P35367 | 5/20 | 0.50 |
| ▸ | HRH2 | P25021 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | CDK2 | P24941 | 7/20 | 0.49 |
| ▸ | GSK3B | P49841 | 6/20 | 0.49 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13146184 | 0.92 | GSK3B (0.50) | CDK2GSK3BCCNE1 | |
| SCHEMBL12954042 | 0.89 | CDK2 (0.62) | HRH4HRH1HRH2HRH3CDK2 | |
| SCHEMBL13304829 | 0.83 | GSK3B (0.51) | CDK2GSK3BCCNE1 | |
| SCHEMBL12953030 | 0.81 | CDK2 (0.66) | CDK2GSK3BCCNE1 | |
| SCHEMBL13304826 | 0.81 | GSK3B (0.52) | CDK2GSK3BCCNE1 | |
| SCHEMBL13305601 | 0.79 | CDK2 (0.54) | CDK2GSK3BCCNE1 | |
| SCHEMBL13304888 | 0.79 | CDK2 (0.54) | CDK2GSK3BCCNE1 | |
| SCHEMBL13146048 | 0.77 | GSK3B (0.77) | CDK2GSK3BCCNE1 | |
| SCHEMBL13304953 | 0.77 | GSK3B (0.49) | CDK2GSK3BCCNE1 | |
| SCHEMBL13146084 | 0.77 | GSK3B (0.49) | CDK2GSK3BCCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1537116-B1 | PYRAZOLOPYRIMIDINES SUITABLE FOR THE TREATMENT OF CANCER DISEASES | SCHERING CORP (US) | 2010-06-02 | — | — | EP | disclosed |